Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,450.00
(
-0.68%
)
US TECH 100
28,593.97
(
-0.69%
)
Dow Jones
49,657.72
(
-0.81%
)
Brent Oil
106.70
(
2.42%
)
Bitcoin
79,266.93
(
-2.21%
)
News Focus
News Focus
Post# of 257577
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122987
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 215049

Monday, 11/27/2017 6:31:56 AM

Monday, November 27, 2017 6:31:56 AM

Post# of 257577
REGN cans Nesvacumab program after phase-2 failures as an addend to Eylea in AMD/DME:

http://investor.regeneron.com/releaseDetail.cfm?ReleaseID=1049746

Regeneron Pharmaceuticals…today announced that results from two Phase 2 studies that added the angiopoietin2 (Ang2) antibody nesvacumab to EYLEA (aflibercept) Injection did not provide sufficient differentiation to warrant Phase 3 development. The RUBY study evaluated patients with diabetic macular edema (DME) and the ONYX study evaluated patients with wet age-related macular degeneration (wet AMD).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today